U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H27N3O2.ClH
Molecular Weight 305.8445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIRACETAM HYDROCHLORIDE

SMILES

CC(C)N(CCN=C(CN1CCCC1=O)O)C(C)C.Cl

InChI

InChIKey=SVIFGEVWHFNGCZ-UHFFFAOYSA-N
InChI=1S/C14H27N3O2.ClH/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19;/h11-12H,5-10H2,1-4H3,(H,15,18);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H27N3O2
Molecular Weight 269.3836
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including http://www.braintropic.com/nootropics/pramiracetam/

Scientists at Parke-Davis first synthesized Pramiracetam (brand name Pramistar) in the late 1970’s. It was first tested with Alzheimer’s patients. Seeing mixed results, the company tried it with major depressive disorder and licensed it as an orphan drug to Menarini. Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. Pramistar is used for the treatment of concentration and memory disturbances caused by the degeneration of brain cells or to diseases of the blood vessels supplying the brain, conditions that arise both in elderly patients (aged over 65 years). By stimulating choline uptake, pramiracetam indirectly modulates the release of acetylcholine and stimulates increased activity in the hippocampus. Because this part of the brain is absolutely crucial to the memory function, the general stimulation that pramiracetam creates can improve both the formation of new memories and the retention of reference or long-term memories. The increased activity in the hippocampus also increases cerebral blood flow, which enhances alertness and improves cognitive abilities in general. Pramiracetam may have other mechanisms of action as well. Researchers have hypothesized that in addition to its action in the brain, pramiracetam acts outside the brain in peripheral sites that rely on the adrenal glands. Animal studies suggest that pramiracetam may also increase or restore brain membrane fluidity, which facilitates cell signaling. Unlike many other racetam class nootropics, pramiracetam does not appear to strongly alter either wakefulness or emotional states. This can be explained by pramiracetam’s very limited influence on the production and release of serotonin, GABA and dopamine, the neurotransmitters that have the greatest effect on mood and anxiety levels.

CNS Activity

Curator's Comment:: pramiracetam penetrates the central nervous system (CNS) poorly

Originator

Curator's Comment:: by scientists at Parke-Davis in the late 1970’s.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: high affinity choline uptake (HACU)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PRAMISTAR

Approved Use

is used for the treatment of concentration and memory disturbances caused by the degeneration of brain cells or to diseases of the blood vessels supplying the brain, conditions that arise both in elderly patients (aged over 65 years).
PubMed

PubMed

TitleDatePubMed
Therapeutic approaches to age-associated neurocognitive disorders.
2001 Sep
[Experience in the application of pramistar, a new nootropic preparation, in the treatment of memory disorders in patients with cerebrovascular pathology].
2003 Dec
Brahmi rasayana improves learning and memory in mice.
2006 Mar
[Application of nootropic agents in complex treatment of patients with concussion of the brain].
2007 Jul-Sep
Diisoprop-yl{2-[2-(2-oxopyrrolidin-1-yl)acetamido]eth-yl}ammonium hydrogen sulfate.
2008 May 30
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
2010 Feb 12

Sample Use Guides

is one tablet of 600 mg twice a day, morning and evening. Swallow the tablets with a drink of water. Do not exceed the daily dose of 1,200 mg.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:00:28 UTC 2021
Edited
by admin
on Sat Jun 26 03:00:28 UTC 2021
Record UNII
WIU553VC0S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRAMIRACETAM HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
PRAMIRACETAM HYDROCHLORIDE [USAN]
Common Name English
PRAMIRACETAM HCL
Common Name English
1-PYRROLIDINEACETAMIDE, N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-OXO-, MONOHYDROCHLORIDE
Systematic Name English
PRAMIRACETAM HYDROCHLORIDE [WHO-DD]
Common Name English
N-(2-(DIISOPROPYLAMINO)ETHYL)-2-OXO-1-PYRROLIDINEACETAMIDE MONOHYDROCHLORIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1509
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
Code System Code Type Description
EVMPD
SUB04005MIG
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
PUBCHEM
3050410
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
MESH
C038438
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
FDA UNII
WIU553VC0S
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
CAS
75733-50-5
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
EPA CompTox
75733-50-5
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL159776
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
NCI_THESAURUS
C72831
Created by admin on Sat Jun 26 03:00:29 UTC 2021 , Edited by admin on Sat Jun 26 03:00:29 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY